Floatz logo

Carboplatin

RET Driver Mutation

Guangdong Provincial People's HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the RET Driver Mutation cohort.

Asset / SponsorPhaseRating
Ceritinib
University of California, San Francisco
Phase 2CCC
Toripalimab
Guangdong Provincial People's Hospital
Phase 2CCC
Regorafenib
University of California, San Francisco
Phase 2CCC
Entrectinib
University of California, San Francisco
Phase 2CCC
Pralsetinib, trans-
Fudan University
Phase 1/2CCC

View all 14 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →